Pharmaceutical manufacturers must adhere to stringent regulations to ensure product safety, efficacy, and quality. Two key regulatory frameworks that guide Good Manufacturing Practices (GMP) are Schedule M (India) and WHO GMP (World Health Organization). While both focus on ensuring high-quality pharmaceutical production, they have distinct requirements and global implications. This blog explores the differences between these two standards and why Schedule M compliance is crucial for Indian manufacturers.
Understanding Schedule M
Schedule M is a part of India’s Drugs and Cosmetics Act, 1945, specifying Good Manufacturing Practices (GMP) for pharmaceutical manufacturers. It outlines infrastructure requirements, quality control measures, documentation practices, and personnel training necessary for maintaining product quality and safety. Adhering to Schedule M ensures that Indian pharmaceutical companies produce safe, effective, and high-quality medicines that meet domestic and global regulatory expectations.
Why Schedule M Compliance Is Essential for Manufacturers
Understanding WHO GMP
WHO GMP is an internationally recognized set of guidelines developed by the World Health Organization (WHO) to ensure that pharmaceutical products meet global safety, quality, and efficacy standards. It serves as a benchmark for many regulatory agencies worldwide and is a requirement for pharmaceutical exports to several international markets.
Key Differences Between Schedule M and WHO GMP
Regulatory Scope
Infrastructure and Facility Requirements
Documentation Practices
Export and Global Recognition
Why Should Manufacturers Align with Both Standards?
Frequently Asked Questions (FAQs)
No, it is not mandatory for domestic sales, but it is required for exports to certain countries.
Yes, many pharmaceutical manufacturers follow both to meet national and international standards.
It ensures legal operation and product quality and forms the foundation for achieving WHO GMP certification for global market entry.